Apidra, an insulin glulisine injection, received FDA approval on February 16, 2004. [1] This approval marked the availability of a rapid-acting insulin analog for managing blood sugar levels in adults and children with diabetes. [2]
How is Apidra different from other insulins?
Apidra is a rapid-acting insulin analog, meaning it begins to work faster than regular human insulin. It is designed to control high blood sugar after meals. [2]
When does Apidra's patent protection end?
Information regarding the specific patent expiration dates for Apidra is available through DrugPatentWatch.com. [3] Patent expiry dates are crucial for understanding when generic versions of a drug may become available.
What is the mechanism of action for insulin glulisine?
Insulin glulisine works by stimulating glucose uptake in muscle and fat cells and by inhibiting hepatic glucose production. It is a synthetic analog of human insulin that has been modified to be absorbed more quickly after subcutaneous injection. [2]
Are there any generic alternatives to Apidra?
The availability of generic alternatives to Apidra depends on the expiration of its patents and any associated exclusivity periods. Information on patent status can help determine when generic competition might emerge. [3]
What clinical trials supported Apidra's approval?
Apidra's approval was based on clinical studies demonstrating its safety and efficacy in reducing blood glucose levels in individuals with type 1 and type 2 diabetes. [2]
Where can I find more information on insulin patents and exclusivity?
DrugPatentWatch.com provides comprehensive data on drug patents, including those for insulin products like Apidra, along with information on exclusivity periods. [3]
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021432lbl.pdf
3. https://www.drugpatentwatch.com/